-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 3, Pien Tze Huang Pharmaceutical's Apixaban tablets were approved for the market.
The product is a new oral anticoagulant with global sales of over US$10 billion
.
Pien Tze Huang has always dominated the field of Chinese patent medicine liver disease in the retail market, and TOP10 brands have seized two seats.
The approval of Apixaban tablets this time marks the company's attack in the field of antithrombotic chemicals
.
The product is a new oral anticoagulant with global sales of over US$10 billion
.
Pien Tze Huang has always dominated the field of Chinese patent medicine liver disease in the retail market, and TOP10 brands have seized two seats.
The approval of Apixaban tablets this time marks the company's attack in the field of antithrombotic chemicals
.
Figure 1: Pien Tze Huang Pharmaceutical's recently approved products
Source: NMPA official website
Apixaban is a highly selective and reversible factor Xa inhibitor.
It is an oral anticoagulant.
It is used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE).
This product is taken Convenient and help improve patient compliance
.
According to data from Meinenet, the global sales of Apixaban in 2020 will exceed 14 billion U.
S.
dollars, in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and urban physical pharmacies in China.
The total terminal sales exceeded 100 million yuan
.
It is an oral anticoagulant.
It is used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE).
This product is taken Convenient and help improve patient compliance
.
According to data from Meinenet, the global sales of Apixaban in 2020 will exceed 14 billion U.
S.
dollars, in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and urban physical pharmacies in China.
The total terminal sales exceeded 100 million yuan
.
Figure 2: 2021E China's urban physical pharmacies TOP 20 manufacturers of proprietary Chinese medicines for liver disease
Source: Mi Nei.
com, China's urban physical pharmacy terminal layout
com, China's urban physical pharmacy terminal layout
Pien Tze Huang Pharmaceutical has become a dominant player in the retail market through its comprehensive channel layout and experience store models
.
In 2021, it is estimated that Pien Tze Huang Pharmaceutical's market share, which has been ranked first in the liver disease drug market of Chinese urban physical pharmacies, will rise to 47.
49%, and half of the country is firmly in hand
.
.
In 2021, it is estimated that Pien Tze Huang Pharmaceutical's market share, which has been ranked first in the liver disease drug market of Chinese urban physical pharmacies, will rise to 47.
49%, and half of the country is firmly in hand
.
Table 1: 2021E liver disease drug brand TOP5
Source: Mi Nei.
com, China's urban physical pharmacy terminal layout
com, China's urban physical pharmacy terminal layout
In 2021E liver disease with drugs brand TOP5, the Pien Tze Huang Pien Tze Huang Pharmaceutical, Pien Tze Huang capsules were occupied TOP1 and TOP3, total sales of over 1 billion yuan
.
.
Pien Tze Huang Pharmaceutical, which has a large variety of Chinese patent medicines, has accelerated the research and development of new products in the field of chemical drugs in recent years.
The apixaban approved for marketing this time is an antithrombotic drug.
This subcategory will be available in Chinese public medical institutions in 2020.
The market size of the terminal exceeds 30 billion yuan
.
In addition, the company's two new class 1 chemical drugs, PZH2108 tablets and PZH2111 tablets, have been approved for clinical trials.
Among them, PZH2111 tablets of advanced solid tumors/hepatic cholangiocellular tumors are undergoing phase I/II clinical trials
.
The apixaban approved for marketing this time is an antithrombotic drug.
This subcategory will be available in Chinese public medical institutions in 2020.
The market size of the terminal exceeds 30 billion yuan
.
In addition, the company's two new class 1 chemical drugs, PZH2108 tablets and PZH2111 tablets, have been approved for clinical trials.
Among them, PZH2111 tablets of advanced solid tumors/hepatic cholangiocellular tumors are undergoing phase I/II clinical trials
.
Source: NMPA official website, Minet database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal!
.
The above sales are calculated based on the average retail price of the product at the terminal!
On November 3, Pien Tze Huang Pharmaceutical's Apixaban tablets were approved for the market.
The product is a new oral anticoagulant with global sales of over US$10 billion
.
Pien Tze Huang has always dominated the field of Chinese patent medicine liver disease in the retail market, and TOP10 brands have seized two seats.
The approval of Apixaban tablets this time marks the company's attack in the field of antithrombotic chemicals
.
The product is a new oral anticoagulant with global sales of over US$10 billion
.
Pien Tze Huang has always dominated the field of Chinese patent medicine liver disease in the retail market, and TOP10 brands have seized two seats.
The approval of Apixaban tablets this time marks the company's attack in the field of antithrombotic chemicals
.
Figure 1: Pien Tze Huang Pharmaceutical's recently approved products
Source: NMPA official website
Apixaban is a highly selective and reversible factor Xa inhibitor.
It is an oral anticoagulant.
It is used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE).
This product is taken Convenient and help improve patient compliance
.
According to data from Meinenet, the global sales of Apixaban in 2020 will exceed 14 billion U.
S.
dollars, in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and urban physical pharmacies in China.
The total terminal sales exceeded 100 million yuan
.
It is an oral anticoagulant.
It is used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE).
This product is taken Convenient and help improve patient compliance
.
According to data from Meinenet, the global sales of Apixaban in 2020 will exceed 14 billion U.
S.
dollars, in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and urban physical pharmacies in China.
The total terminal sales exceeded 100 million yuan
.
Figure 2: 2021E China's urban physical pharmacies TOP 20 manufacturers of proprietary Chinese medicines for liver disease
Source: Mi Nei.
com, China's urban physical pharmacy terminal layout
com, China's urban physical pharmacy terminal layout
Pien Tze Huang Pharmaceutical has become a dominant player in the retail market through its comprehensive channel layout and experience store models
.
In 2021, it is estimated that Pien Tze Huang Pharmaceutical's market share, which has been ranked first in the liver disease drug market of Chinese urban physical pharmacies, will rise to 47.
49%, and half of the country is firmly in hand
.
.
In 2021, it is estimated that Pien Tze Huang Pharmaceutical's market share, which has been ranked first in the liver disease drug market of Chinese urban physical pharmacies, will rise to 47.
49%, and half of the country is firmly in hand
.
Table 1: 2021E liver disease drug brand TOP5
Source: Mi Nei.
com, China's urban physical pharmacy terminal layout
com, China's urban physical pharmacy terminal layout
In 2021E liver disease with drugs brand TOP5, the Pien Tze Huang Pien Tze Huang Pharmaceutical, Pien Tze Huang capsules were occupied TOP1 and TOP3, total sales of over 1 billion yuan
.
.
Pien Tze Huang Pharmaceutical, which has a large variety of Chinese patent medicines, has accelerated the research and development of new products in the field of chemical drugs in recent years.
The apixaban approved for marketing this time is an antithrombotic drug.
This subcategory will be available in Chinese public medical institutions in 2020.
The market size of the terminal exceeds 30 billion yuan
.
In addition, the company's two new class 1 chemical drugs, PZH2108 tablets and PZH2111 tablets, have been approved for clinical trials.
Among them, PZH2111 tablets of advanced solid tumors/hepatic cholangiocellular tumors are undergoing phase I/II clinical trials
.
The apixaban approved for marketing this time is an antithrombotic drug.
This subcategory will be available in Chinese public medical institutions in 2020.
The market size of the terminal exceeds 30 billion yuan
.
In addition, the company's two new class 1 chemical drugs, PZH2108 tablets and PZH2111 tablets, have been approved for clinical trials.
Among them, PZH2111 tablets of advanced solid tumors/hepatic cholangiocellular tumors are undergoing phase I/II clinical trials
.
Source: NMPA official website, Minet database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal!
.
The above sales are calculated based on the average retail price of the product at the terminal!
On November 3, Pien Tze Huang Pharmaceutical's Apixaban tablets were approved for the market.
The product is a new oral anticoagulant with global sales of over US$10 billion
.
Pien Tze Huang has always dominated the field of Chinese patent medicine liver disease in the retail market, and TOP10 brands have seized two seats.
The approval of Apixaban tablets this time marks the company's attack in the field of antithrombotic chemicals
.
The product is a new oral anticoagulant with global sales of over US$10 billion
.
Pien Tze Huang has always dominated the field of Chinese patent medicine liver disease in the retail market, and TOP10 brands have seized two seats.
The approval of Apixaban tablets this time marks the company's attack in the field of antithrombotic chemicals
.
Figure 1: Pien Tze Huang Pharmaceutical's recently approved products
Source: NMPA official website
Apixaban is a highly selective and reversible factor Xa inhibitor.
It is an oral anticoagulant.
It is used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE).
This product is taken Convenient and help improve patient compliance
.
According to data from Meinenet, the global sales of Apixaban in 2020 will exceed 14 billion U.
S.
dollars, in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and urban physical pharmacies in China.
The total terminal sales exceeded 100 million yuan
.
Hospital hospital hospital pharmacy pharmacy pharmacyIt is an oral anticoagulant.
It is used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE).
This product is taken Convenient and help improve patient compliance
.
According to data from Meinenet, the global sales of Apixaban in 2020 will exceed 14 billion U.
S.
dollars, in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and urban physical pharmacies in China.
The total terminal sales exceeded 100 million yuan
.
Figure 2: 2021E China's urban physical pharmacies TOP 20 manufacturers of proprietary Chinese medicines for liver disease
Source: Mi Nei.
com, China's urban physical pharmacy terminal layout
com, China's urban physical pharmacy terminal layout
Pien Tze Huang Pharmaceutical has become a dominant player in the retail market through its comprehensive channel layout and experience store models
.
In 2021, it is estimated that Pien Tze Huang Pharmaceutical's market share, which has been ranked first in the liver disease drug market of Chinese urban physical pharmacies, will rise to 47.
49%, and half of the country is firmly in hand
.
.
In 2021, it is estimated that Pien Tze Huang Pharmaceutical's market share, which has been ranked first in the liver disease drug market of Chinese urban physical pharmacies, will rise to 47.
49%, and half of the country is firmly in hand
.
Table 1: 2021E liver disease drug brand TOP5
Source: Mi Nei.
com, China's urban physical pharmacy terminal layout
com, China's urban physical pharmacy terminal layout
In 2021E liver disease with drugs brand TOP5, the Pien Tze Huang Pien Tze Huang Pharmaceutical, Pien Tze Huang capsules were occupied TOP1 and TOP3, total sales of over 1 billion yuan
.
Medicine, medicine, medicine.
Pien Tze Huang Pharmaceutical, which has a large variety of Chinese patent medicines, has accelerated the research and development of new products in the field of chemical drugs in recent years.
The apixaban approved for marketing this time is an antithrombotic drug.
This subcategory will be available in Chinese public medical institutions in 2020.
The market size of the terminal exceeds 30 billion yuan
.
In addition, the company's two new class 1 chemical drugs, PZH2108 tablets and PZH2111 tablets, have been approved for clinical trials.
Among them, PZH2111 tablets of advanced solid tumors/hepatic cholangiocellular tumors are undergoing phase I/II clinical trials
.
Tumor tumor tumorThe apixaban approved for marketing this time is an antithrombotic drug.
This subcategory will be available in Chinese public medical institutions in 2020.
The market size of the terminal exceeds 30 billion yuan
.
In addition, the company's two new class 1 chemical drugs, PZH2108 tablets and PZH2111 tablets, have been approved for clinical trials.
Among them, PZH2111 tablets of advanced solid tumors/hepatic cholangiocellular tumors are undergoing phase I/II clinical trials
.
Source: NMPA official website, Minet database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal!
.
The above sales are calculated based on the average retail price of the product at the terminal!
